A large body of evidence indicates that GNG7 is downregulated in various tumors, including esophageal cancer [67], lung adenocarcinoma [68], clear cell renal cell carcinoma [69], etc. In gastrointestinal tract cancer, GNG7 suppresses cell growth in vitro and in vivo by upregulating the expression of the cyclin-dependent kinase inhibitor p27Kip1 [66]. Here, CDKN1B is linked to digestive system cancer.